Ratings LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Real-time Estimate Cboe BZX Other stock markets 09:25:36 12/06/2024 pm IST			5-day change	1st Jan Change
5.605 ^USD	+6.16%		-2.61%	-28.48%

10/06	Transcript : LifeStance Health Group, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:00 AM
29/05	Lifestance Health Group Insider Sold Shares Worth $22,395,812, According to a Recent SEC Filing	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 48% by 2026.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is highly valued given the cash flows generated by its activity.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
LIFESTANCE HEALTH GROUP, INC.	-28.48%	2.02B		D+
HCA HEALTHCARE, INC.	+26.43%	88.08B		C+
CVS HEALTH CORPORATION	-23.87%	75.32B		B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+3.45%	28.19B		C+
FRESENIUS SE & CO. KGAA	+7.05%	17.78B		A-
LABCORP HOLDINGS INC.	-12.61%	16.64B		B
QUEST DIAGNOSTICS INCORPORATED	+1.45%	15.64B		A-
NATERA, INC.	+81.67%	13.81B		C-
PURE HEALTH HOLDING	-26.67%	13.01B	-	-
UNIVERSAL HEALTH SERVICES, INC.	+23.64%	12.43B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes